Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc. NASDAQ
CAPR at a glance
Capricor Therapeutics, Inc. (CAPR): Hold, 41/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($7.82 and $21.88).
- Insiders Insiders sold $8.4M and made no open-market purchases over the last 18 months.
As of October 15, 2026, Capricor Therapeutics, Inc. (CAPR) trades at $6.590. Wall Street's consensus target is $25.00 across 10 analysts. The 14-day RSI (daily closes) is 34, showing bearish momentum without being oversold, and the price is below its 50-day simple moving average of $7.819.
Figures as of October 15, 2026.
Only on CleaRank
Figures we compute ourselves from CAPR's own price, earnings and insider-filing history. Tap one to see it in context.
CAPR Price Analysis
Market Metrics
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
CAPR Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
| Report | EPS estimate | EPS actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Feb 16, 2026 | -$10.85 | -$0.59 | +94.56% | +10.86% | +21.19% |
| Nov 13, 2025 | -$0.50 | $0.13 | +126.00% | -2.95% | -1.39% |
Reports after February 16, 2026 are not yet in our data.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
As of October 15, 2026, CAPR has beaten the analyst EPS estimate in 2 of its last 2 reported quarters and fell in the first trading session after 1 of those beats; its most recent report in our data, on February 16, 2026, came in 94.56% above the estimate and the stock moved +10.86% in the first session.
CAPR Analysis
- Capricor Therapeutics (CAPR) is trading below its 50-day and 200-day moving averages ($7.82 and $21.88), indicating a bearish trend; consider waiting for a confirmed break above these levels before initiating new positions.
- With a negative EPS and 0.00% profit margin, investors should be aware of the company's burn rate and consider position sizing carefully, especially given the moderate insider selling.
Positive results from ongoing clinical trials for Capricor's lead candidates could significantly boost investor confidence and drive the stock price higher.
Source: Company Pipeline UpdatesRecent analyst upgrades from firms like B. Riley Securities and Piper Sandler suggest a potentially improving outlook, which could lead to further positive price action if sustained.
Source: Wall Street Analyst RatingsInsiders have sold approximately $8.4 million worth of stock with no reported purchases, indicating a moderate sell signal that could weigh on investor sentiment.
Source: Insider Transaction FilingsThe stock is trading below its 50-day and 20-day moving averages, with a bearish RSI status, suggesting continued downward pressure in the short term.
Source: Technical Chart AnalysisKey Statistics
| Market Cap | 383.72M |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -2.57 |
| Dividend Yield | 0.00% |
| 52 Week High | 40.37 |
| 52 Week Low | 2.96 |
As of October 15, 2026, CAPR trades at $6.59, with a market value of $383.72M and no P/E ratio (its trailing earnings are negative).
Earnings & Growth Analysis
Key Risks
Technical Indicators
| RSI (14-day) | 33.55 |
|---|---|
| MACD (12, 26) | -0.496 |
| SMA (50-day) | 7.82 |
| SMA (200-day) | 21.88 |
As of October 15, 2026, with CAPR at $6.59, its 14-day RSI is 33.6 (showing bearish momentum without being oversold), its 50-day simple moving average is $7.82 and its 200-day is $21.88.
Calculated by CleaRank on daily closes as of October 15, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
As of October 15, 2026, CAPR's 1-year correlation of daily returns is +0.10 with S&P 500 (SPY), +0.09 with Nasdaq 100 (QQQ), +0.01 with Bitcoin (BTC) and -0.03 with gold (XAU).
How does any other asset move with CAPR? One year of daily closes, Pearson correlation.
CAPR Wall Street View
12-month price targets
The price, $6.59, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 14, 2026 | B. Riley Securities | Upgrade | Buy |
| Sep 1, 2026 | Piper Sandler | Upgrade | Overweight |
| Aug 14, 2026 | Cantor Fitzgerald | Upgrade | Overweight |
| Jul 31, 2026 | Jones Trading | Downgrade | Hold |
| Jul 30, 2026 | Piper Sandler | Downgrade | Neutral |
| Jul 30, 2026 | Cantor Fitzgerald | Downgrade | Neutral |
As of October 15, 2026, 10 Wall Street analysts cover CAPR: 4 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $7.00 to $54.00, with a median of $25.00, 279.4% above the price of $6.59.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CAPR Trade Plans
Specific entry, exit, and risk management levels
Entry Strategies pick an entry style
Risk Management
Profit Targets (Based on Conservative Entry)
CAPR moves about 5.1% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Growth of $10,000
A $10,000 investment in CAPR in October 2016 would be worth about $1,967 today, compared with about $36,237 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
CAPR Drawdowns & Recovery
As of October 15, 2026, CAPR's worst peak-to-trough fall over the last 10 years was -97.0% (October 2016 to April 2020); it regained that peak by April 2026, 72 months after the low, and 52% of 1-year holding periods ended with a gain.
From weekly closing values. A drawdown is the fall from the highest value reached so far to a later low.
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CAPR today could grow to about $5,733 by 2036 in the base case, with a 90th-percentile outcome near $43,496 and a 10th-percentile outcome around $756. Projections are statistical simulations, not guarantees.
CAPR Stock Price Prediction: 2030
CleaRank's simulation projects a price near $5.28 for CAPR by 2030 in the base case, from $6.59 today (0.8x over 4 years). The 10th-percentile path ends near $1.46. These are outcomes of a Monte Carlo simulation run on CAPR's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile |
|---|---|---|---|
| 2027 | $3.28 | $6.23 | $11.83 |
| 2028 | $2.38 | $5.90 | $14.59 |
| 2029 | $1.84 | $5.58 | $16.92 |
| 2030 | $1.46 | $5.28 | $19.00 |
| 2031 | $1.19 | $4.99 | $20.91 |
Method: a lognormal simulation of CAPR's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
People Also Watch
CAPR Insider Trading Analysis
As of October 15, 2026, CAPR insiders reported 10 open-market sales worth $8.4M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 25, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Sell | 24.1K | $732.2K |
| Jun 25, 2026 | KRASNEY KAREN
General Counsel
|
Sell | 24.1K | $732.2K |
| Jun 25, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Option | 24.1K | $76.6K |
| Jun 25, 2026 | KRASNEY KAREN
General Counsel
|
Option | 24.1K | $76.6K |
| Jun 24, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Sell | 900 | $27.0K |
| Jun 24, 2026 | KRASNEY KAREN
General Counsel
|
Sell | 900 | $27.0K |
| Jun 24, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Option | 900 | $2.9K |
| Jun 24, 2026 | KRASNEY KAREN
General Counsel
|
Option | 900 | $2.9K |
| May 18, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Option | 3.0K | $4.2K |
| May 13, 2026 | LITVACK FRANK I
Director
|
Option | 3.9K | $5.5K |